Climb Bio presented Phase 2 data for budoprutug, an anti-CD19 antibody, showing effective B-cell depletion and reduction of PLA2R antibodies in primary membranous nephropathy (pMN) patients at 12 weeks. The 200 mg dose demonstrated immunologic remission consistent with earlier Phase 1b results, while 600 mg showed deeper B-cell depletion. Budoprutug was well tolerated with mostly mild side effects. A separate case study in minimal change disease (MCD) showed three-year steroid-free remission, supporting further research. These findings highlight budoprutug's potential as a new treatment for immune-mediated kidney diseases, with more data expected in 2027.
Climb Bio's budoprutug Phase 2 data is the story's subject. For readers following health stocks, here is Pluang's market snapshot as of Oct 25, 2026 06:41 WIB: out of 150 priced US health stocks, 44 rose and 105 fell. Notable movers include BNGO at USD 1.13 (-4.24%), ENVB at USD 1.40 (-4.11%), and TLRY at USD 2.81 (-4.10%) with a 35% sell / 65% buy order split on Pluang.
Palantir has guided its revenue for the third quarter of 2026 to reach $2.16 billion. This forecast is supported by the company's performance in the last two quarters, which suggests that actual results could surpass expectations. The strong revenue ...
Evernorth Holdings, a Nasdaq-listed company managing a large XRP treasury, is collaborating with the Fuzzies community to release limited merchandise celebrating the historic Fuzzybear wallet activated in 2013. This initiative honors early XRP suppor...
Hyperliquid (HYPE) is currently priced around $76, needing a 19.2% rise to hit the $90 target set by many holders. Despite a strong 107% gain over 200 days, HYPE has fallen 17.1% in the last month, pressured by a growing unlocked token supply and a r...
Quebec's maple syrup reserve, stored in warehouses with a capacity of about 218,000 barrels, is expected to be depleted by February. This reserve helps balance supply fluctuations caused by weather, which strongly affects syrup production. Canadian s...
Bitcoin has experienced significant price declines during U.S. midterm election cycles in 2010, 2014, 2018, and 2022, with drops ranging from 27% to 72%. However, the exact timing and cause of these declines are unclear due to lack of detailed data. ...
